| abstract |
57 The present invention discloses a compound of the formula:n where R 1 is hydrogen or the group -C(R 3 )(R 5 )-R 4 , where R 3 and R 4 are the same or different and are hydrogen, C 1 to C 12 linear or branched alkyl, C 3 to C 7 cycloalkyl, C 6 to C 10 aryl unsubstituted or substituted with C 1 to C 6 linear or branched alkyl, C 1 to C 6 linear or branched alkoxy, nitro, amino, amino substituted with at least one C 1 to C 6 linear or branched alkyl or phenyl, C 2 to C 10 aralkyl, C 4 to C 8 heteroaryl wherein said heteroatom is nitrogen, phosphorous, sulfur or oxygen, and R 2 is hydrogen, or taken together with Rs, forms a chemical bond, and R is a monosaccharide radical selected from the group consisting essentially of glucose, fructose, ribose, 2-deoxyribose, mannose, galactose, xylose and arabinose. The compounds prepared by the present invention are therapeutically effective adenosine receptor agonists in mammals. Thus, they are effective for treating conditions which respond to selective adenosine A 2 receptor stimulation (particularly adenosine-2). Accordingly, the compounds of the present invention are useful for treating hypertension, thrombosis and atherosclerosis and for causing coronary vasodilation. |